Evidence map›Paper›PMID 37414918›Full record

SynthesisHeart failure reviews2023

ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis.

Yu Gao, Ruiting Wang, Jinchi Jiang, Yueyao Hu, Haijing Li, Yong Wang

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Heart failure reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 4 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 4 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yu Gao *College of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.
Ruiting Wang *Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China.
Jinchi JiangGraduate School, Beijing University of Chinese Medicine, Beijing, 100029, China.
Yueyao HuGraduate School, Beijing University of Chinese Medicine, Beijing, 100029, China.
Haijing LiCollege of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.
Yong WangCollege of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China. wangyong@bucm.edu.cn.
Beijing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anthracyclines and trastuzumab are widely used to treat breast cancer but increase the risk of cardiomyopathy and heart failure. With the use of trastuzumab and anthracycline-containing medications, this study intends to evaluate the effectiveness and security of current treatments against cardiotoxicity. We conducted a systematic review of randomized controlled trials (RCTs), which used at least one angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or beta-blocker (BB) to prevent cardiotoxicity of antineoplastic agents for breast cancer, in 4 databases (PubMed, Cochrane Library, EMBASE, Web of Science) from inception to 11 May 2022, without language restrictions. The outcome of interest was left ventricular ejection fraction (LVEF) and adverse events. Stata 15 and R software 4.2.1 were used to perform all statistical analyses. The Cochrane version 2 of the risk of bias tool was used to assess the risk of bias, and the grading of recommendations assessment, development, and evaluation (GRADE) assessment was used to appraise the quality of the evidence. Fifteen randomized clinical studies with a total of 1977 patients were included in the analysis. The included studies demonstrated statistically significant LVEF in the ACEI/ARB and BB treatment groups (χ

Indexed as

Antineoplastic AgentsBreast NeoplasmsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAnthracyclinesAntibiotics, AntineoplasticCardiotoxicityFemaleHumansRandomized Controlled Trials as TopicTrastuzumabAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAnthracyclinesAntibiotics, AntineoplasticAntineoplastic AgentsTrastuzumabACEI/ARBBeta-blockerBreast cancerCardiotoxicityLVEF

Identifiers

PMID37414918
PMCPMC10575808
OpenAlexW4383483103

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.